Palbociclib: tested in a combination
124 studies: another drug in the study is under test too. Page 2 of 2. Open to participants first (40), then studies with results posted, then the rest; newest registration first within each.
- Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02942355Phase 2Report a problem
- Palbociclib With Cisplatin or Carboplatin in Advanced Solid TumorsCompletedNCT02897375Phase 1Report a problem
- Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT02760030Phase 2Report a problem
- Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial CancerCompletedNCT02730429Phase 2Report a problem
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2Report a problem
- PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialActive, not recruitingNCT02624973Phase 2Report a problem
- Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Active, not recruitingNCT02605486Phase 1/2Report a problem
- Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node MetastasesActive, not recruitingNCT02603679Phase 2Report a problem
- A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCStatus unknownNCT02592746Phase 2Report a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2Report a problem
- Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast CancerCompletedNCT02448420Phase 2Report a problem
- Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal WomenCompletedNCT02400567Phase 2Report a problem
- A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of PalbociclibCompletedNCT02311946Phase 1Report a problem
- Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)CompletedNCT02222441Phase 1Report a problem
- Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell LymphomaActive, not recruitingNCT02159755Phase 1Report a problem
- Effect Of Itraconazole On The Pharmacokinetics Of PalbociclibCompletedNCT02131298Phase 1Report a problem
- Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And FoodCompletedNCT02097329Phase 1Report a problem
- Relative Bioavailability For Palbociclib FormulationsCompletedNCT02083640Phase 1Report a problem
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid TumorsCompletedNCT02065063Phase 1Report a problem
- Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted ConditionsCompletedNCT02041273Phase 1Report a problem
- Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT02030483Phase 1Report a problem
- PALBOCICLIB + PD-0325901 for NSCLC & Solid TumorsCompletedNCT02022982Phase 1Report a problem
- Characterization Of The Effect Of Food On Palbociclib (PD-0332991) AbsorptionCompletedNCT01904747Phase 1Report a problem
- A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)CompletedNCT01802476Phase 1Report a problem